Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib tosylate tablets plus KN046 injection in advanced gastrointestinal solid tumors (phase I/II)
CTR20202151Phase 2Terminated
- Sponsor
- Zelgen
- Start
- Nov 2020
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib, erfonrilimab in gastric cancer (GC), esophageal cancer, colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic cancer (PC), sponsored by Zelgen. Started Nov 2020; status: terminated.
02
Drugs
donafeniberfonrilimab
03
Conditions
gastric cancer (GC)esophageal cancercolorectal cancer (CRC)hepatocellular carcinoma (HCC)pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20202151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202151.